Associated Papers
Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial.
Renneville A et al.
Oncotarget, 2014
24659740 (PubMed )
Supplement: oncotarget-05-916-s001.pdf
Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.
Wen XM et al.
International Journal of Clinical and Experimental Pathology, 2014
CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk.
Park SH et al.
Leukemia Research, 2013
Select a paper to view details